341 related articles for article (PubMed ID: 26211834)
1. Tim-3 and Tim-4 as the potential targets for antitumor therapy.
Cheng L; Ruan Z
Hum Vaccin Immunother; 2015; 11(10):2458-62. PubMed ID: 26211834
[TBL] [Abstract][Full Text] [Related]
2. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of TIM-3 and CEACAM1 promotes T cell exhaustion in colorectal cancer patients.
Zhang Y; Cai P; Li L; Shi L; Chang P; Liang T; Yang Q; Liu Y; Wang L; Hu L
Int Immunopharmacol; 2017 Feb; 43():210-218. PubMed ID: 28038383
[TBL] [Abstract][Full Text] [Related]
4. NK cell expression of Tim-3: First impressions matter.
So EC; Khaladj-Ghom A; Ji Y; Amin J; Song Y; Burch E; Zhou H; Sun H; Chen S; Bentzen S; Hertzano R; Zhang X; Strome SE
Immunobiology; 2019 May; 224(3):362-370. PubMed ID: 30876792
[TBL] [Abstract][Full Text] [Related]
5. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.
Huang YH; Zhu C; Kondo Y; Anderson AC; Gandhi A; Russell A; Dougan SK; Petersen BS; Melum E; Pertel T; Clayton KL; Raab M; Chen Q; Beauchemin N; Yazaki PJ; Pyzik M; Ostrowski MA; Glickman JN; Rudd CE; Ploegh HL; Franke A; Petsko GA; Kuchroo VK; Blumberg RS
Nature; 2015 Jan; 517(7534):386-90. PubMed ID: 25363763
[TBL] [Abstract][Full Text] [Related]
6. Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models.
Ma S; Tian Y; Peng J; Chen C; Peng X; Zhao F; Li Z; Li M; Zhao F; Sheng X; Zong R; Li Y; Zhang J; Yu M; Zhu Q; Tian X; Li Y; Neckenig MR; Liu H; Zhan P; Yue X; Wu Z; Gao L; Liang X; Liu X; Li C; Ma C
Sci Transl Med; 2023 Nov; 15(722):eadg6752. PubMed ID: 37967204
[TBL] [Abstract][Full Text] [Related]
7. Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas.
Baghdadi M; Nagao H; Yoshiyama H; Akiba H; Yagita H; Dosaka-Akita H; Jinushi M
Cancer Immunol Immunother; 2013 Apr; 62(4):629-37. PubMed ID: 23143694
[TBL] [Abstract][Full Text] [Related]
8. Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas.
Li J; Liu X; Duan Y; Liu Y; Wang H; Lian S; Zhuang G; Fan Y
Med Sci Monit; 2017 Jul; 23():3593-3602. PubMed ID: 28736431
[TBL] [Abstract][Full Text] [Related]
9. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade.
da Silva IP; Gallois A; Jimenez-Baranda S; Khan S; Anderson AC; Kuchroo VK; Osman I; Bhardwaj N
Cancer Immunol Res; 2014 May; 2(5):410-22. PubMed ID: 24795354
[TBL] [Abstract][Full Text] [Related]
10. Tim-3 and its role in regulating anti-tumor immunity.
Das M; Zhu C; Kuchroo VK
Immunol Rev; 2017 Mar; 276(1):97-111. PubMed ID: 28258697
[TBL] [Abstract][Full Text] [Related]
11. Tim-3, a negative regulator of anti-tumor immunity.
Anderson AC
Curr Opin Immunol; 2012 Apr; 24(2):213-6. PubMed ID: 22226204
[TBL] [Abstract][Full Text] [Related]
12. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer.
Xu B; Yuan L; Gao Q; Yuan P; Zhao P; Yuan H; Fan H; Li T; Qin P; Han L; Fang W; Suo Z
Oncotarget; 2015 Aug; 6(24):20592-603. PubMed ID: 26008981
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
14. Blocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune response.
Baghdadi M; Takeuchi S; Wada H; Seino K
MAbs; 2014; 6(5):1124-32. PubMed ID: 25517298
[TBL] [Abstract][Full Text] [Related]
15. T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B.
Ju Y; Hou N; Meng J; Wang X; Zhang X; Zhao D; Liu Y; Zhu F; Zhang L; Sun W; Liang X; Gao L; Ma C
J Hepatol; 2010 Mar; 52(3):322-9. PubMed ID: 20133006
[TBL] [Abstract][Full Text] [Related]
16. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors.
Sauer N; Janicka N; Szlasa W; Skinderowicz B; Kołodzińska K; Dwernicka W; Oślizło M; Kulbacka J; Novickij V; Karłowicz-Bodalska K
Cancer Immunol Immunother; 2023 Nov; 72(11):3405-3425. PubMed ID: 37567938
[TBL] [Abstract][Full Text] [Related]
17. The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer.
Wang Z; Zhu J; Gu H; Yuan Y; Zhang B; Zhu D; Zhou J; Zhu Y; Chen W
Immunol Invest; 2015; 44(6):578-89. PubMed ID: 26214042
[TBL] [Abstract][Full Text] [Related]
18. PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation.
Kong Y; Zhang J; Claxton DF; Ehmann WC; Rybka WB; Zhu L; Zeng H; Schell TD; Zheng H
Blood Cancer J; 2015 Jul; 5(7):e330. PubMed ID: 26230954
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of T cell immunoglobulin- and mucin domain-containing molecule-3 on natural killer cells in atherogenesis.
Hou N; Zhao D; Liu Y; Gao L; Liang X; Liu X; Gai X; Zhang X; Zhu F; Ni M; Zhang Y; Sun W; Ma C
Atherosclerosis; 2012 May; 222(1):67-73. PubMed ID: 22387059
[TBL] [Abstract][Full Text] [Related]
20. TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action.
Du W; Yang M; Turner A; Xu C; Ferris RL; Huang J; Kane LP; Lu B
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28300768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
